Diagnostic testing for hypertension, diabetes, and hypercholesterolaemia in low-income and middle-income countries: a cross-sectional study of data for 994 185 individuals from 57 nationally representative surveys.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
09 2023
Historique:
received: 13 03 2023
revised: 06 06 2023
accepted: 07 06 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: ppublish

Résumé

Testing for the risk factors of cardiovascular disease, which include hypertension, diabetes, and hypercholesterolaemia, is important for timely and effective risk management. Yet few studies have quantified and analysed testing of cardiovascular risk factors in low-income and middle-income countries (LMICs) with respect to sociodemographic inequalities. We aimed to address this knowledge gap. In this cross-sectional analysis, we pooled individual-level data for non-pregnant adults aged 18 years or older from nationally representative surveys done between Jan 1, 2010, and Dec 31, 2019 in LMICs that included a question about whether respondents had ever had their blood pressure, glucose, or cholesterol measured. We analysed diagnostic testing performance by quantifying the overall proportion of people who had ever been tested for these cardiovascular risk factors and the proportion of individuals who met the diagnostic testing criteria in the WHO package of essential noncommunicable disease interventions for primary care (PEN) guidelines (ie, a BMI >30 kg/m Our sample included data for 994 185 people from 57 surveys. 19·1% (95% CI 18·5-19·8) of the 943 259 people in the hypertension sample met the WHO PEN criteria for diagnostic testing, of whom 78·6% (77·8-79·2) were tested. 23·8% (23·4-24·3) of the 225 707 people in the diabetes sample met the WHO PEN criteria for diagnostic testing, of whom 44·9% (43·7-46·2) were tested. Finally, 27·4% (26·3-28·6) of the 250 573 people in the hypercholesterolaemia sample met the WHO PEN criteria for diagnostic testing, of whom 39·7% (37·1-2·4) were tested. Women were more likely than men to be tested for hypertension and diabetes, and people in higher wealth quintiles compared with those in the lowest wealth quintile were more likely to be tested for all three risk factors, as were people with at least secondary education compared with those with less than primary education. Our study shows opportunities for health systems in LMICs to improve the targeting of diagnostic testing for cardiovascular risk factors and adherence to diagnostic testing guidelines. Risk-factor-based testing recommendations rather than sociodemographic characteristics should determine which individuals are tested. Harvard McLennan Family Fund, the Alexander von Humboldt Foundation, and the National Heart, Lung, and Blood Institute of the US National Institutes of Health.

Sections du résumé

BACKGROUND
Testing for the risk factors of cardiovascular disease, which include hypertension, diabetes, and hypercholesterolaemia, is important for timely and effective risk management. Yet few studies have quantified and analysed testing of cardiovascular risk factors in low-income and middle-income countries (LMICs) with respect to sociodemographic inequalities. We aimed to address this knowledge gap.
METHODS
In this cross-sectional analysis, we pooled individual-level data for non-pregnant adults aged 18 years or older from nationally representative surveys done between Jan 1, 2010, and Dec 31, 2019 in LMICs that included a question about whether respondents had ever had their blood pressure, glucose, or cholesterol measured. We analysed diagnostic testing performance by quantifying the overall proportion of people who had ever been tested for these cardiovascular risk factors and the proportion of individuals who met the diagnostic testing criteria in the WHO package of essential noncommunicable disease interventions for primary care (PEN) guidelines (ie, a BMI >30 kg/m
FINDINGS
Our sample included data for 994 185 people from 57 surveys. 19·1% (95% CI 18·5-19·8) of the 943 259 people in the hypertension sample met the WHO PEN criteria for diagnostic testing, of whom 78·6% (77·8-79·2) were tested. 23·8% (23·4-24·3) of the 225 707 people in the diabetes sample met the WHO PEN criteria for diagnostic testing, of whom 44·9% (43·7-46·2) were tested. Finally, 27·4% (26·3-28·6) of the 250 573 people in the hypercholesterolaemia sample met the WHO PEN criteria for diagnostic testing, of whom 39·7% (37·1-2·4) were tested. Women were more likely than men to be tested for hypertension and diabetes, and people in higher wealth quintiles compared with those in the lowest wealth quintile were more likely to be tested for all three risk factors, as were people with at least secondary education compared with those with less than primary education.
INTERPRETATION
Our study shows opportunities for health systems in LMICs to improve the targeting of diagnostic testing for cardiovascular risk factors and adherence to diagnostic testing guidelines. Risk-factor-based testing recommendations rather than sociodemographic characteristics should determine which individuals are tested.
FUNDING
Harvard McLennan Family Fund, the Alexander von Humboldt Foundation, and the National Heart, Lung, and Blood Institute of the US National Institutes of Health.

Identifiants

pubmed: 37591584
pii: S2214-109X(23)00280-2
doi: 10.1016/S2214-109X(23)00280-2
pmc: PMC10480389
mid: NIHMS1925307
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1363-e1371

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL161271
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Lancet Healthy Longev. 2021 Jun;2(6):e340-e351
pubmed: 35211689
Lancet. 2021 Jul 17;398(10296):238-248
pubmed: 34274065
PLoS Med. 2021 Oct 25;18(10):e1003841
pubmed: 34695124
Lancet. 2021 Nov 27;398(10315):1997-2050
pubmed: 34626542
Lancet. 2019 May 18;393(10185):2018-2020
pubmed: 31106735
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Obes Rev. 2012 Mar;13(3):275-86
pubmed: 22106927
PLoS Med. 2019 Mar 1;16(3):e1002751
pubmed: 30822339
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Int J Epidemiol. 2022 Dec 13;51(6):e337-e349
pubmed: 35762972

Auteurs

Sophie Ochmann (S)

Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Goettingen, Germany.

Isabelle von Polenz (I)

Faculty of Medicine, University of Goettingen, Goettingen, Germany.

Maja-Emilia Marcus (ME)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

Michaela Theilmann (M)

Heidelberg Institute of Global Health, Faculty of Medicine, and University Hospital, Heidelberg University, Heidelberg, Germany.

David Flood (D)

University of Michigan, Ann Arbor, MI, USA.

Kokou Agoudavi (K)

Togo Ministry of Health, Lome, Togo.

Krishna Kumar Aryal (KK)

Bergen Center for Ethics and Priority Setting, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway.

Silver Bahendeka (S)

Saint Francis Hospital Nsambya, Uganda Martyrs University, Kampala, Uganda.

Brice Bicaba (B)

Institut National de Santé Publique, Ouagadougou, Burkina Faso.

Pascal Bovet (P)

Ministry of Health, Victoria, Seychelles; University Center for General Medicine and Public Health (Unisanté), Lausanne, Switzerland.

Luisa Campos Caldeira Brant (L)

Department of Clinical Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Deborah Carvalho Malta (D)

Postgraduate Program in Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Albertino Damasceno (A)

Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Farshad Farzadfar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Gladwell Gathecha (G)

Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya.

Ali Ghanbari (A)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mongal Gurung (M)

Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan.

David Guwatudde (D)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda.

Corine Houehanou (C)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Dismand Houinato (D)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Nahla Hwalla (N)

Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon.

Jutta Adelin Jorgensen (JA)

Global Health Section, Dept of Public Health, University of Copenhagen, Cophenhagen, Denmark.

Khem B Karki (KB)

Department of Community Medicine and Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.

Nuno Lunet (N)

Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; EPIUnit, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal; Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional, Porto, Portugal.

Joao Martins (J)

Faculty of Medicine and Health Sciences, Universidade Nacional Timor Lorosa'e, Dili, Timor-Leste.

Mary Mayige (M)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Sahar Saeedi Moghaddam (SS)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Kiel Institute for the World Economy, Kiel, Germany.

Omar Mwalim (O)

Bergen Center for Ethics and Priority Setting, Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway; Ministry of Health, Zanzibar City, Tanzania.

Kibachio Joseph Mwangi (KJ)

Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Bolormaa Norov (B)

Nutrition Division, National Center for Public Health, Ulaanbaatar, Mongolia.

Sarah Quesnel-Crooks (S)

Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago.

Negar Rezaei (N)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Abla M Sibai (AM)

Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.

Lela Sturua (L)

Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia.

Lindiwe Tsabedze (L)

Ministry of Health, Mbabane, Eswatini.

Roy Wong-McClure (R)

Office of Epidemiology and Surveillance, Caja Costarricense de Seguro Social, San José, Costa Rica.

Justine Davies (J)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK; MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape Town, South Africa.

Pascal Geldsetzer (P)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.

Till Bärnighausen (T)

Heidelberg Institute of Global Health, Faculty of Medicine, and University Hospital, Heidelberg University, Heidelberg, Germany; Harvard Center for Population and Development Studies, Cambridge, MA, USA; Africa Health Research Institute, KwaZulu-Natal, South Africa.

Rifat Atun (R)

Department of Global Health and Social Medicine, Boston, MA, USA; Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.

Jennifer Manne-Goehler (J)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.

Sebastian Vollmer (S)

Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Goettingen, Germany. Electronic address: sebastian.vollmer@wiwi.uni-goettingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH